Company news

Biotron Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Executive Director CEO Commences - Appendix 3X

November 8, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Biotron Receives Additional $208,463 Tax Refund

October 22, 2026

Annual Report/Notice of AGM/Proxy Form

October 22, 2026

Director Appointment Michael Thurn & Appendix 3X

October 18, 2026

Appointment of CEO and Executive Director

October 13, 2026

Resignation of Managing Director and Appendix 3Z

September 13, 2026

Change of Share Registry

September 3, 2026

Investor Presentation

September 2, 2026

Appendix 4G

August 26, 2026

Corporate Governance Statement

August 26, 2026

Full Year Statutory Accounts and Appendix 4E

August 26, 2026

Change in substantial holding

August 17, 2026

HBV Treatment to Progress Towards Human Trials

August 16, 2026

Sedarex First Milestone Met

July 12, 2026

$525K R&D Rebate Received

June 3, 2026

Hepatitis B Virus Program Update

March 17, 2026

Half Yearly Report and Accounts

February 26, 2026

Successful Issue of the Entitlement Offer Shortfall

January 29, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 28, 2026

Security Class Reinstatement to Quotation - BITO

December 21, 2025

Rights Issue Close

December 19, 2025

Security Class Suspension from Quotation - BITO

December 14, 2025

Non-Renounceable rights Issue Prospectus

November 18, 2025

Acquisition of Sedarex Limited and $2.5m capital raising

October 15, 2025

Trading Halt

October 12, 2025

Pause in Trading

October 12, 2025

Full Year Statutory Accounts and Appendix 4E

August 27, 2025

Rights Issue Closed

April 7, 2025

Replacement Prospectus

March 12, 2025

Response to ASX Query Letter

March 12, 2025

Supplementary Prospectus

March 4, 2025

Response to ASX Aware Query

March 3, 2025

Prospectus

March 2, 2025

Renounceable Rights Issue

February 27, 2025

Updated Appendix 4C

February 3, 2025

Agreement with C14 Consulting Group

November 26, 2024

$1.8M R&D Rebate Received

October 13, 2024

BIT225-012 Phase 2 COVID-19 clinical trial

September 5, 2024

BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives

June 19, 2024

Positive outcomes in BIT225 phase 2 clinical trial in hiv

April 4, 2024

Response to ASX Price Query

March 26, 2024

Completion of Phase 2 COVID clinical trial

August 16, 2023

Second Site Approved for Phase 2 Covid-19 Trial

May 12, 2023

Commencement Phase 2 Covid-19 Clinical Trial

May 3, 2023

Completion of Phase 2 HIV-1 Clinical Trials

March 8, 2023

International Presentation of BIT225 COVID-19 Data

February 20, 2023

$1.43M R&D rebate received

November 18, 2022

Commencement of Rights Trading - BITRC

October 31, 2022

Renounceable Issue

October 26, 2022

Older news releases →

Decks

The 5 newest of 101 decks. Every deck is listed under its year.